Octreotide Long Acting Release
Phase 3Completed 0 watching 0 views this weekπ Rising
77
Development Stage
β
Pre-clinicalβ
Phase 1β
Phase 24
Phase 35
ApprovedIndication / Disease
Chemotherapy-induced Diarrhea
Conditions
Chemotherapy-induced Diarrhea
Trial Timeline
Apr 1, 2008 β Sep 1, 2010
NCT ID
NCT00582426About Octreotide Long Acting Release
Octreotide Long Acting Release is a phase 3 stage product being developed by Novartis for Chemotherapy-induced Diarrhea. The current trial status is completed. This product is registered under clinical trial identifier NCT00582426. Target conditions include Chemotherapy-induced Diarrhea.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00582426 | Phase 3 | Completed |
Competing Products
20 competing products in Chemotherapy-induced Diarrhea